Close Menu

Selventa

Selventa and Rosa plan to combine knowledge assets, proprietary data, physiologic model libraries, and expertise in several disease areas with the aim of helping clients make better drug discovery and development decisions.

The two firms' combined modeling and analysis will integrate genomic, transcriptomic, in vitro, animal, and clinical data in a quantitative model.

Jeremy Berg is stepping down from NIGMS, Timothy Triche is named to Wafergen's scientific advisory board, and Uwe Neue has died.

The company said it will focus on providing consulting services and software, and help its clients select patient-specific treatments.

Pages

CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.

Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.

Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.

In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.